CareFusion (CFN) Announces 5-Year Distribution Agreement with ResMed (RMD)
Get Alerts CFN Hot Sheet
Join SI Premium – FREE
CareFusion (NYSE: CFN) and ResMed (NYSE: RMD) announced a five-year agreement providing CareFusion the exclusive right to distribute the ResMed Stellarâ„¢ 100 and 150 non-invasive ventilators (NIV) and their related accessories into the U.S. institutional healthcare market.
The agreement, effective immediately, provides strategic benefits to both companies. CareFusion will now have a more competitive offering in the institutional NIV market, which is expected to grow by more than 6 percent annually. For ResMed, it provides a timely introduction of its new ventilation products, with their unique performance, size and mobility features valuable to clinicians, caregivers and patients, via CareFusion's long-standing relationships with U.S. hospitals, long-term acute care and skilled nursing facilities. CareFusion will also market and sell the Stellar 100 and 150 related accessories, including tubing and filters.
The agreement, effective immediately, provides strategic benefits to both companies. CareFusion will now have a more competitive offering in the institutional NIV market, which is expected to grow by more than 6 percent annually. For ResMed, it provides a timely introduction of its new ventilation products, with their unique performance, size and mobility features valuable to clinicians, caregivers and patients, via CareFusion's long-standing relationships with U.S. hospitals, long-term acute care and skilled nursing facilities. CareFusion will also market and sell the Stellar 100 and 150 related accessories, including tubing and filters.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share